(NASDAQ: ALZN) Alzamend Neuro's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 16.35%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.94%.
Alzamend Neuro's earnings in 2026 is -$8,772,382.On average, 3 Wall Street analysts forecast ALZN's earnings for 2027 to be -$12,707,124, with the lowest ALZN earnings forecast at -$12,208,806, and the highest ALZN earnings forecast at -$13,080,863. On average, 3 Wall Street analysts forecast ALZN's earnings for 2028 to be -$14,857,561, with the lowest ALZN earnings forecast at -$14,274,911, and the highest ALZN earnings forecast at -$15,294,548.
In 2029, ALZN is forecast to generate -$4,203,126 in earnings, with the lowest earnings forecast at -$4,038,297 and the highest earnings forecast at -$4,326,747.